Stock code: 688321 Stock abbreviation: Chipscreen Biosciences Announcement No.: 2025-008

Shenzhen Microchip Biotechnology Co., Ltd

2024 Annual Results Advance Announcement

The board of directors and all directors of the company guarantee that there are no false records, misleading statements or material omissions in the content of this announcement, and assume legal responsibility for the authenticity, accuracy and completeness of its content in accordance with the law.

1. Forecast of performance for the current period

(1) The performance forecast period

January 1, 2024 to December 31, 2024.

(2) Performance forecast

(1) The company expects to achieve an annual operating income of 657.8468 million yuan in 2024

right, a year-on-year increase of about 25.61%.

(2) The company expects to achieve a net profit attributable to shareholders of listed companies in 2024 of about 111.4337 million yuan, a decrease of about 200.2722 million yuan over the same period of the previous year, a year-on-year decrease of about 225.43%.

(3) The company expects to achieve a net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses in 2024 of about 202.9016 million yuan, a decrease of about 14.5973 million yuan over the loss of the same period last year, and a year-on-year loss of about 6.71%.

(3) The relevant financial data of this performance forecast have not been audited by certified public accountants.

Second, the performance of the same period last year

The company's annual operating income in 2023 will be 523.7102 million yuan, which is attributable to listing

The net profit of the company's shareholders was 88.8385 million yuan, and the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was -217.4989 million yuan.

3. The main reasons for the change in the performance of the current period

(1) During the reporting period, the sales volume of the company's products chidamide and siglitamida sodium increased significantly, so the operating income increased accordingly.

(2) During the reporting period, with the gradual maturity of the company's own sales team, the company and Zhejiang Hisun Pharmaceutical Co., Ltd. (hereinafter referred to as "Hisun Pharmaceutical") agreed to terminate the agreement on siglitat sodium tablets (dilopin? Exclusive Licensing and Joint Marketing Strategic Cooperation Agreement. The unamortized license fee of about 65.00 million yuan paid to the company in the early stage and the clinical trial fee of about 17.00 million yuan in the relevant period should be paid to the company in the performance of the contract, which are included in the profit or loss of the current period (the exact amount is to be finally confirmed by both parties).

(3) During the reporting period, based on the results of clinical trials and changes in current clinical diagnosis and treatment practices, the company decided not to submit the marketing application for the monotherapy of cioroni for the treatment of third-line and above small cell lung cancer, and accordingly made a full provision for asset impairment of the balance of the project's development expenditure of about 90 million yuan, and correspondingly reduced the company's total annual profit in 2024 by about 90 million yuan.

4. Risk Warning

As of the date of this announcement, the company has not found any major uncertainties that may affect the accuracy of the content of this performance forecast.

5. Other explanatory matters

The above forecast data is only preliminary accounting data, and the specific and accurate financial data are subject to the audited 2024 annual report officially disclosed by the company.

The announcement is hereby made.

Board of Directors of Shenzhen Microchip Biotechnology Co., Ltd

January 18, 2025